PMID- 34287841
OWN - NLM
STAT- MEDLINE
DCOM- 20211203
LR  - 20211214
IS  - 1600-0404 (Electronic)
IS  - 0001-6314 (Linking)
VI  - 145
IP  - 1
DP  - 2022 Jan
TI  - Safety and efficacy of Direct Oral Anticoagulants in cerebral venous thrombosis: 
      A meta-analysis.
PG  - 10-23
LID - 10.1111/ane.13506 [doi]
AB  - Cerebral venous thrombosis (CVT) is caused by partial or complete occlusion of 
      the major cerebral venous sinuses or the smaller feeding cortical veins which 
      predispose to the risk of venous infarction and hemorrhage. Current guidelines 
      recommend treating CVT with either low-molecular-weight heparin (LMWH) or 
      unfractionated heparin (UFH) followed by an oral vitamin K antagonist (VKA) for 
      3-12 months. Direct oral anticoagulants (DOACs) have already established benefit 
      over warfarin as a long-term treatment of symptomatic venous thromboembolic 
      disorder like deep vein thrombosis (DVT), and pulmonary embolism (PE) given its 
      equal efficacy and better safety profile. The benefit of DOACs over warfarin as a 
      long-term anticoagulation for CVT has likewise been extensively studied, yet it 
      has not been approved as first-line therapy in the current practice. We therefore 
      performed a systematic review and meta-analysis of relevant studies to generate 
      robust evidence regarding the safety and efficacy of DOACs in CVT. This 
      meta-analysis demonstrates that the use of DOACs in CVT has similar efficacy and 
      safety compared to VKAs with better recanalization rate.
CI  - (c) 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Nepal, Gaurav
AU  - Nepal G
AUID- ORCID: 0000-0001-5054-2711
AD  - Department of Internal Medicine, Maharajgunj Medical Campus, Tribhuvan University 
      Institute of Medicine, Maharajgunj, Kathmandu, Nepal.
FAU - Kharel, Sanjeev
AU  - Kharel S
AUID- ORCID: 0000-0001-9591-3168
AD  - Department of Internal Medicine, Maharajgunj Medical Campus, Tribhuvan University 
      Institute of Medicine, Maharajgunj, Kathmandu, Nepal.
FAU - Bhagat, Riwaj
AU  - Bhagat R
AD  - Department of Neurology, University of Louisville School of Medicine, Louisville, 
      KY, USA.
FAU - Ka Shing, Yow
AU  - Ka Shing Y
AD  - Department of Internal Medicine, National University Hospital, Singapore, 
      Singapore.
FAU - Ariel Coghlan, Megan
AU  - Ariel Coghlan M
AD  - Department of Neurology, University of Louisville School of Medicine, Louisville, 
      KY, USA.
FAU - Poudyal, Prasanta
AU  - Poudyal P
AD  - Department of Otorhinolaryngology, Tribhuvan University Teaching Hospital, 
      Maharajgunj, Kathmandu, Nepal.
FAU - Ojha, Rajeev
AU  - Ojha R
AUID- ORCID: 0000-0001-7680-7036
AD  - Department of Neurology, Tribhuvan University Teaching Hospital, Maharajgunj, 
      Kathmandu, Nepal.
FAU - Sunder Shrestha, Gentle
AU  - Sunder Shrestha G
AD  - Department of Anesthesiology, Tribhuvan University Teaching Hospital, 
      Maharajgunj, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20210721
PL  - Denmark
TA  - Acta Neurol Scand
JT  - Acta neurologica Scandinavica
JID - 0370336
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants/adverse effects
MH  - Heparin/therapeutic use
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - *Venous Thromboembolism/drug therapy
MH  - *Venous Thrombosis/drug therapy
OTO - NOTNLM
OT  - CVST
OT  - CVT
OT  - DOAC
OT  - NOAC
OT  - apixaban
OT  - cerebral venous thrombosis
OT  - dabigatran
OT  - edoxaban
OT  - rivaroxaban
EDAT- 2021/07/22 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/07/21 13:08
PHST- 2021/06/25 00:00 [revised]
PHST- 2021/05/11 00:00 [received]
PHST- 2021/07/11 00:00 [accepted]
PHST- 2021/07/22 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/07/21 13:08 [entrez]
AID - 10.1111/ane.13506 [doi]
PST - ppublish
SO  - Acta Neurol Scand. 2022 Jan;145(1):10-23. doi: 10.1111/ane.13506. Epub 2021 Jul 
      21.